de Rosen continued, "Also, 2007 was another year of strong Vancocin performance; we achieved net product sales of $204 million, representing growth of 22 percent over that of 2006. We anticipate that our new marketing initiatives will help us garner additional growth in 2008 and beyond, potentially offsetting a slow down in the incidence rate of C. difficile infection (CDI). At ViroPharma, we take our commitment to the safety of patients with CDI very seriously. Through our efforts during the year, physicians were better educated to identify patients at high risk of disease, hospitals are better equipped to control CDI, and patients at risk of severe and complicated disease were assured of a proven safe and effective treatment. Importantly, though, our efforts in CDI are also focused on future treatment alternatives: we made progress toward a potential future treatment for disease recurrence, called NTCD, which we expect to enter the clinic this year."
Net income in the fourth quarter and twelve months ended December 31,
2007 was $20.4 million and $95.4 million, respectively, compared to net
income of $18.0 million and $66.7 million for the same periods in 2006. Net
income per share for the quarter ended December 31, 2007 was $0.29 per
share, basic and $0.25 per share, diluted, compared to a net income of
$0.26 per share, basic, and $0.25 per share, diluted, for the same period
in 2006. Net income per share for the twelve months ended December 31, 2007
was $1.37 pe
|SOURCE ViroPharma Incorporated|
Copyright©2008 PR Newswire.
All rights reserved